earnings and earnings per Class A Common share
for the nine
months ended December 31, 2007
(unaudited)
Income Effect
Per Share Amount
Income as reported (GAAP) $1.40 $79,900,000
After-tax effect of write-off of acquired
in-process research and development $.11 $6,500,000
Earnings and Earnings per Class A common
share - assuming dilution, excluding effect
of acquired in-process research and
development write-off $1.51 $86,400,000
'/>"/>SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine news :1.
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board2.
Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference3.
VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 20084.
Lotus Pharmaceuticals Raises $5 Million in Private Placement5.
Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals6.
Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference7.
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results8.
RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia9.
Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled10.
60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG11.
KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE